AXGN
AxoGen, Inc. NASDAQ$42.63
Mkt Cap $2.3B
52w Low $9.22
91.3% of range
52w High $45.83
50d MA $33.83
200d MA $25.82
P/E (TTM)
-127.3x
EV/EBITDA
7765.2x
P/B
15.5x
Debt/Equity
0.1x
ROE
-12.8%
P/FCF
-513.9x
RSI (14)
—
ATR (14)
—
Beta
0.98
50d MA
$33.83
200d MA
$25.82
Avg Volume
1.1M
About
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucos…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | TNS | 0.12 | 0.07 | -41.7% | 41.99 | -1.1% | -0.5% | +2.9% | +3.1% | — | — | — | — |
| Feb 24, 2026 | TNS | 0.09 | 0.07 | -21.2% | 32.50 | -1.7% | -3.9% | -1.8% | -2.4% | -5.7% | -8.2% | -0.8% | — |
| Oct 29, 2025 | TNS | 0.09 | 0.12 | +33.3% | 22.25 | +3.0% | +1.9% | -0.1% | +4.5% | +6.8% | +5.1% | +28.8% | — |
| Aug 5, 2025 | TNS | 0.06 | 0.12 | +100.0% | 13.72 | +2.0% | +0.2% | +2.6% | +1.3% | +2.1% | +3.2% | +12.2% | — |
| May 8, 2025 | TNS | -0.01 | -0.02 | -100.0% | 12.59 | +2.2% | -9.7% | -9.5% | -13.6% | -6.1% | -6.4% | -17.3% | — |
| Feb 25, 2025 | TNS | 0.04 | 0.08 | +100.0% | 20.11 | +2.8% | -3.2% | -3.4% | -0.5% | -4.1% | -7.4% | -5.6% | — |
| Nov 7, 2024 | TNS | 0.01 | 0.07 | +1066.7% | 13.27 | +0.4% | -4.6% | +5.3% | +0.0% | -5.5% | -6.0% | +10.6% | — |
| Aug 8, 2024 | TNS | -0.05 | 0.05 | +200.0% | 10.70 | +4.2% | +3.0% | +1.6% | +5.2% | +0.5% | +3.0% | +21.7% | — |
| May 2, 2024 | TNS | -0.10 | -0.06 | +40.0% | 5.88 | +0.2% | -1.5% | -3.6% | -0.9% | -0.2% | +1.7% | +16.0% | — |
| Mar 5, 2024 | TNS | -0.09 | -0.06 | +33.3% | 8.99 | -0.9% | +0.8% | +0.3% | -2.7% | -6.1% | -8.5% | -13.7% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | Wells Fargo | Maintains | Overweight → Overweight | — | $41.99 | $41.52 | -1.1% | -0.5% | +2.9% | +3.1% | — | — |
| Apr 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.99 | $41.52 | -1.1% | -0.5% | +2.9% | +3.1% | — | — |
| Apr 29 | Citizens | Maintains | Market Outperform → Market Outperform | — | $41.99 | $41.52 | -1.1% | -0.5% | +2.9% | +3.1% | — | — |
| Apr 29 | Canaccord Genuity | Maintains | Buy → Buy | — | $41.99 | $41.52 | -1.1% | -0.5% | +2.9% | +3.1% | — | — |
| Apr 23 | Lake Street | Maintains | Buy → Buy | — | $37.00 | $37.32 | +0.9% | +1.1% | +6.1% | +6.5% | +13.5% | +12.9% |
| Mar 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $31.28 | $31.26 | -0.1% | +0.1% | +5.9% | +7.4% | +10.1% | +4.3% |
| Feb 24 | Citizens | Maintains | Market Outperform → Market Outperform | — | $35.38 | $29.62 | -16.3% | -8.1% | -11.8% | -9.8% | -10.3% | -13.4% |
| Dec 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.85 | $32.95 | +0.3% | +1.4% | -6.3% | -6.8% | -8.6% | -8.7% |
| Dec 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $32.85 | $32.95 | +0.3% | +1.4% | -6.3% | -6.8% | -8.6% | -8.7% |
| Dec 4 | Jefferies | Maintains | Buy → Buy | — | $28.33 | $31.07 | +9.7% | +16.0% | +17.6% | +8.7% | +8.0% | +5.9% |
Recent Filings
8-K · 7.01
! Medium
Axogen, Inc. -- 8-K 7.01: Regulation FD Disclosure
Axogen disclosed a financial results presentation available for investor and analyst discussions, though the filing provides limited detail on specific business updates or financial performance metrics.
Apr 28
8-K · 7.01
! Medium
Axogen, Inc. -- 8-K 7.01: Regulation FD Disclosure
Axogen furnished a financial results presentation for potential use with analysts and investors, signaling routine investor communication and transparency regarding company performance.
Feb 24
Data updated apr 24, 2026 8:11pm
· Source: massive.com